Working with primary human blood cells

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038149

Enrollment

Registered

2025-10-23

Start date

2025-07-23

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmunity

Interventions

Group 1: PBMCs or specifically purified immune cell populations from 60 volunteers (> 18 years of age over a period of 3 years) are treated pharmacologically or genetically modified (e.g. using CRISPR

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: healthy

Exclusion criteria

Exclusion criteria: Negative for hepatitis B (HBs-Ag), hepatitis C (HCV-Ab), HIV (1 and 2 Ab+Ag) and syphilis (antibody screening test)

Design outcomes

Primary

Measure	Time frame
The aim of the investigations is to characterise the influence of pharmacological and genetic manipulations on the activation of the human immune response. On this basis, new therapeutic strategies against autoimmune diseases are to be evaluated and possible side effects better assessed.	—

Countries

Germany

Contacts

Public ContactKamyar Hadian

Helmholtz Zentrum München GmbH

kamyar.hadian@helmholtz-munich.de+49 89 3187 2664

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026